Global Dermatomyositis Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Dermatomyositis Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Dermatomyositis Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Dermatomyositis Drug by Country/Region, 2017, 2022 & 2028

2.2 Dermatomyositis Drug Segment by Type

2.2.1 Abatacept

2.2.2 Baricitinib

2.2.3 Dalazatide

2.2.4 Immune Globulin

2.2.5 IMO-8400

2.2.6 Others

2.3 Dermatomyositis Drug Sales by Type

2.3.1 Global Dermatomyositis Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Dermatomyositis Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Dermatomyositis Drug Sale Price by Type (2017-2022)

2.4 Dermatomyositis Drug Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Dermatomyositis Drug Sales by Application

2.5.1 Global Dermatomyositis Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Dermatomyositis Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Dermatomyositis Drug Sale Price by Application (2017-2022)

3 Global Dermatomyositis Drug by Company

3.1 Global Dermatomyositis Drug Breakdown Data by Company

3.1.1 Global Dermatomyositis Drug Annual Sales by Company (2020-2022)

3.1.2 Global Dermatomyositis Drug Sales Market Share by Company (2020-2022)

3.2 Global Dermatomyositis Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Dermatomyositis Drug Revenue by Company (2020-2022)

3.2.2 Global Dermatomyositis Drug Revenue Market Share by Company (2020-2022)

3.3 Global Dermatomyositis Drug Sale Price by Company

3.4 Key Manufacturers Dermatomyositis Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Dermatomyositis Drug Product Location Distribution

3.4.2 Players Dermatomyositis Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Dermatomyositis Drug by Geographic Region

4.1 World Historic Dermatomyositis Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Dermatomyositis Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Dermatomyositis Drug Annual Revenue by Geographic Region

4.2 World Historic Dermatomyositis Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Dermatomyositis Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Dermatomyositis Drug Annual Revenue by Country/Region

4.3 Americas Dermatomyositis Drug Sales Growth

4.4 APAC Dermatomyositis Drug Sales Growth

4.5 Europe Dermatomyositis Drug Sales Growth

4.6 Middle East & Africa Dermatomyositis Drug Sales Growth

5 Americas

5.1 Americas Dermatomyositis Drug Sales by Country

5.1.1 Americas Dermatomyositis Drug Sales by Country (2017-2022)

5.1.2 Americas Dermatomyositis Drug Revenue by Country (2017-2022)

5.2 Americas Dermatomyositis Drug Sales by Type

5.3 Americas Dermatomyositis Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Dermatomyositis Drug Sales by Region

6.1.1 APAC Dermatomyositis Drug Sales by Region (2017-2022)

6.1.2 APAC Dermatomyositis Drug Revenue by Region (2017-2022)

6.2 APAC Dermatomyositis Drug Sales by Type

6.3 APAC Dermatomyositis Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Dermatomyositis Drug by Country

7.1.1 Europe Dermatomyositis Drug Sales by Country (2017-2022)

7.1.2 Europe Dermatomyositis Drug Revenue by Country (2017-2022)

7.2 Europe Dermatomyositis Drug Sales by Type

7.3 Europe Dermatomyositis Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Dermatomyositis Drug by Country

8.1.1 Middle East & Africa Dermatomyositis Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Dermatomyositis Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Dermatomyositis Drug Sales by Type

8.3 Middle East & Africa Dermatomyositis Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Dermatomyositis Drug

10.3 Manufacturing Process Analysis of Dermatomyositis Drug

10.4 Industry Chain Structure of Dermatomyositis Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Dermatomyositis Drug Distributors

11.3 Dermatomyositis Drug Customer

12 World Forecast Review for Dermatomyositis Drug by Geographic Region

12.1 Global Dermatomyositis Drug Market Size Forecast by Region

12.1.1 Global Dermatomyositis Drug Forecast by Region (2023-2028)

12.1.2 Global Dermatomyositis Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Dermatomyositis Drug Forecast by Type

12.7 Global Dermatomyositis Drug Forecast by Application

13 Key Players Analysis

13.1 MedImmune LLC

13.1.1 MedImmune LLC Company Information

13.1.2 MedImmune LLC Dermatomyositis Drug Product Offered

13.1.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 MedImmune LLC Main Business Overview

13.1.5 MedImmune LLC Latest Developments

13.2 Neovacs SA

13.2.1 Neovacs SA Company Information

13.2.2 Neovacs SA Dermatomyositis Drug Product Offered

13.2.3 Neovacs SA Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Neovacs SA Main Business Overview

13.2.5 Neovacs SA Latest Developments

13.3 Novartis AG

13.3.1 Novartis AG Company Information

13.3.2 Novartis AG Dermatomyositis Drug Product Offered

13.3.3 Novartis AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Novartis AG Main Business Overview

13.3.5 Novartis AG Latest Developments

13.4 Octapharma AG

13.4.1 Octapharma AG Company Information

13.4.2 Octapharma AG Dermatomyositis Drug Product Offered

13.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Octapharma AG Main Business Overview

13.4.5 Octapharma AG Latest Developments

13.5 Pfizer Inc

13.5.1 Pfizer Inc Company Information

13.5.2 Pfizer Inc Dermatomyositis Drug Product Offered

13.5.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Pfizer Inc Main Business Overview

13.5.5 Pfizer Inc Latest Developments

13.6 Eli Lilly and Company

13.6.1 Eli Lilly and Company Company Information

13.6.2 Eli Lilly and Company Dermatomyositis Drug Product Offered

13.6.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Eli Lilly and Company Main Business Overview

13.6.5 Eli Lilly and Company Latest Developments

13.7 F. Hoffmann-La Roche Ltd

13.7.1 F. Hoffmann-La Roche Ltd Company Information

13.7.2 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product Offered

13.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 F. Hoffmann-La Roche Ltd Main Business Overview

13.7.5 F. Hoffmann-La Roche Ltd Latest Developments

13.8 Hope Pharmaceuticals Inc

13.8.1 Hope Pharmaceuticals Inc Company Information

13.8.2 Hope Pharmaceuticals Inc Dermatomyositis Drug Product Offered

13.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Hope Pharmaceuticals Inc Main Business Overview

13.8.5 Hope Pharmaceuticals Inc Latest Developments

13.9 Idera Pharmaceuticals Inc

13.9.1 Idera Pharmaceuticals Inc Company Information

13.9.2 Idera Pharmaceuticals Inc Dermatomyositis Drug Product Offered

13.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Idera Pharmaceuticals Inc Main Business Overview

13.9.5 Idera Pharmaceuticals Inc Latest Developments

13.10 KPI Therapeutics Inc

13.10.1 KPI Therapeutics Inc Company Information

13.10.2 KPI Therapeutics Inc Dermatomyositis Drug Product Offered

13.10.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 KPI Therapeutics Inc Main Business Overview

13.10.5 KPI Therapeutics Inc Latest Developments

13.11 Marathon Pharmaceuticals LLC

13.11.1 Marathon Pharmaceuticals LLC Company Information

13.11.2 Marathon Pharmaceuticals LLC Dermatomyositis Drug Product Offered

13.11.3 Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Marathon Pharmaceuticals LLC Main Business Overview

13.11.5 Marathon Pharmaceuticals LLC Latest Developments

14 Research Findings and Conclusion

Table 1. Dermatomyositis Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Dermatomyositis Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Abatacept

Table 4. Major Players of Baricitinib

Table 5. Major Players of Dalazatide

Table 6. Major Players of Immune Globulin

Table 7. Major Players of IMO-8400

Table 8. Major Players of Others

Table 9. Global Dermatomyositis Drug Sales by Type (2017-2022) & (K Pcs)

Table 10. Global Dermatomyositis Drug Sales Market Share by Type (2017-2022)

Table 11. Global Dermatomyositis Drug Revenue by Type (2017-2022) & ($ million)

Table 12. Global Dermatomyositis Drug Revenue Market Share by Type (2017-2022)

Table 13. Global Dermatomyositis Drug Sale Price by Type (2017-2022) & (USD/Pcs)

Table 14. Global Dermatomyositis Drug Sales by Application (2017-2022) & (K Pcs)

Table 15. Global Dermatomyositis Drug Sales Market Share by Application (2017-2022)

Table 16. Global Dermatomyositis Drug Revenue by Application (2017-2022)

Table 17. Global Dermatomyositis Drug Revenue Market Share by Application (2017-2022)

Table 18. Global Dermatomyositis Drug Sale Price by Application (2017-2022) & (USD/Pcs)

Table 19. Global Dermatomyositis Drug Sales by Company (2020-2022) & (K Pcs)

Table 20. Global Dermatomyositis Drug Sales Market Share by Company (2020-2022)

Table 21. Global Dermatomyositis Drug Revenue by Company (2020-2022) ($ Millions)

Table 22. Global Dermatomyositis Drug Revenue Market Share by Company (2020-2022)

Table 23. Global Dermatomyositis Drug Sale Price by Company (2020-2022) & (USD/Pcs)

Table 24. Key Manufacturers Dermatomyositis Drug Producing Area Distribution and Sales Area

Table 25. Players Dermatomyositis Drug Products Offered

Table 26. Dermatomyositis Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Dermatomyositis Drug Sales by Geographic Region (2017-2022) & (K Pcs)

Table 30. Global Dermatomyositis Drug Sales Market Share Geographic Region (2017-2022)

Table 31. Global Dermatomyositis Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 32. Global Dermatomyositis Drug Revenue Market Share by Geographic Region (2017-2022)

Table 33. Global Dermatomyositis Drug Sales by Country/Region (2017-2022) & (K Pcs)

Table 34. Global Dermatomyositis Drug Sales Market Share by Country/Region (2017-2022)

Table 35. Global Dermatomyositis Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 36. Global Dermatomyositis Drug Revenue Market Share by Country/Region (2017-2022)

Table 37. Americas Dermatomyositis Drug Sales by Country (2017-2022) & (K Pcs)

Table 38. Americas Dermatomyositis Drug Sales Market Share by Country (2017-2022)

Table 39. Americas Dermatomyositis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 40. Americas Dermatomyositis Drug Revenue Market Share by Country (2017-2022)

Table 41. Americas Dermatomyositis Drug Sales by Type (2017-2022) & (K Pcs)

Table 42. Americas Dermatomyositis Drug Sales Market Share by Type (2017-2022)

Table 43. Americas Dermatomyositis Drug Sales by Application (2017-2022) & (K Pcs)

Table 44. Americas Dermatomyositis Drug Sales Market Share by Application (2017-2022)

Table 45. APAC Dermatomyositis Drug Sales by Region (2017-2022) & (K Pcs)

Table 46. APAC Dermatomyositis Drug Sales Market Share by Region (2017-2022)

Table 47. APAC Dermatomyositis Drug Revenue by Region (2017-2022) & ($ Millions)

Table 48. APAC Dermatomyositis Drug Revenue Market Share by Region (2017-2022)

Table 49. APAC Dermatomyositis Drug Sales by Type (2017-2022) & (K Pcs)

Table 50. APAC Dermatomyositis Drug Sales Market Share by Type (2017-2022)

Table 51. APAC Dermatomyositis Drug Sales by Application (2017-2022) & (K Pcs)

Table 52. APAC Dermatomyositis Drug Sales Market Share by Application (2017-2022)

Table 53. Europe Dermatomyositis Drug Sales by Country (2017-2022) & (K Pcs)

Table 54. Europe Dermatomyositis Drug Sales Market Share by Country (2017-2022)

Table 55. Europe Dermatomyositis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 56. Europe Dermatomyositis Drug Revenue Market Share by Country (2017-2022)

Table 57. Europe Dermatomyositis Drug Sales by Type (2017-2022) & (K Pcs)

Table 58. Europe Dermatomyositis Drug Sales Market Share by Type (2017-2022)

Table 59. Europe Dermatomyositis Drug Sales by Application (2017-2022) & (K Pcs)

Table 60. Europe Dermatomyositis Drug Sales Market Share by Application (2017-2022)

Table 61. Middle East & Africa Dermatomyositis Drug Sales by Country (2017-2022) & (K Pcs)

Table 62. Middle East & Africa Dermatomyositis Drug Sales Market Share by Country (2017-2022)

Table 63. Middle East & Africa Dermatomyositis Drug Revenue by Country (2017-2022) & ($ Millions)

Table 64. Middle East & Africa Dermatomyositis Drug Revenue Market Share by Country (2017-2022)

Table 65. Middle East & Africa Dermatomyositis Drug Sales by Type (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Dermatomyositis Drug Sales Market Share by Type (2017-2022)

Table 67. Middle East & Africa Dermatomyositis Drug Sales by Application (2017-2022) & (K Pcs)

Table 68. Middle East & Africa Dermatomyositis Drug Sales Market Share by Application (2017-2022)

Table 69. Key Market Drivers & Growth Opportunities of Dermatomyositis Drug

Table 70. Key Market Challenges & Risks of Dermatomyositis Drug

Table 71. Key Industry Trends of Dermatomyositis Drug

Table 72. Dermatomyositis Drug Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Dermatomyositis Drug Distributors List

Table 75. Dermatomyositis Drug Customer List

Table 76. Global Dermatomyositis Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 77. Global Dermatomyositis Drug Sales Market Forecast by Region

Table 78. Global Dermatomyositis Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 79. Global Dermatomyositis Drug Revenue Market Share Forecast by Region (2023-2028)

Table 80. Americas Dermatomyositis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 81. Americas Dermatomyositis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 82. APAC Dermatomyositis Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 83. APAC Dermatomyositis Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 84. Europe Dermatomyositis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 85. Europe Dermatomyositis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Middle East & Africa Dermatomyositis Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 87. Middle East & Africa Dermatomyositis Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 88. Global Dermatomyositis Drug Sales Forecast by Type (2023-2028) & (K Pcs)

Table 89. Global Dermatomyositis Drug Sales Market Share Forecast by Type (2023-2028)

Table 90. Global Dermatomyositis Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 91. Global Dermatomyositis Drug Revenue Market Share Forecast by Type (2023-2028)

Table 92. Global Dermatomyositis Drug Sales Forecast by Application (2023-2028) & (K Pcs)

Table 93. Global Dermatomyositis Drug Sales Market Share Forecast by Application (2023-2028)

Table 94. Global Dermatomyositis Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 95. Global Dermatomyositis Drug Revenue Market Share Forecast by Application (2023-2028)

Table 96. MedImmune LLC Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. MedImmune LLC Dermatomyositis Drug Product Offered

Table 98. MedImmune LLC Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 99. MedImmune LLC Main Business

Table 100. MedImmune LLC Latest Developments

Table 101. Neovacs SA Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. Neovacs SA Dermatomyositis Drug Product Offered

Table 103. Neovacs SA Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 104. Neovacs SA Main Business

Table 105. Neovacs SA Latest Developments

Table 106. Novartis AG Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 107. Novartis AG Dermatomyositis Drug Product Offered

Table 108. Novartis AG Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 109. Novartis AG Main Business

Table 110. Novartis AG Latest Developments

Table 111. Octapharma AG Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 112. Octapharma AG Dermatomyositis Drug Product Offered

Table 113. Octapharma AG Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 114. Octapharma AG Main Business

Table 115. Octapharma AG Latest Developments

Table 116. Pfizer Inc Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 117. Pfizer Inc Dermatomyositis Drug Product Offered

Table 118. Pfizer Inc Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 119. Pfizer Inc Main Business

Table 120. Pfizer Inc Latest Developments

Table 121. Eli Lilly and Company Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 122. Eli Lilly and Company Dermatomyositis Drug Product Offered

Table 123. Eli Lilly and Company Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 124. Eli Lilly and Company Main Business

Table 125. Eli Lilly and Company Latest Developments

Table 126. F. Hoffmann-La Roche Ltd Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 127. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product Offered

Table 128. F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 129. F. Hoffmann-La Roche Ltd Main Business

Table 130. F. Hoffmann-La Roche Ltd Latest Developments

Table 131. Hope Pharmaceuticals Inc Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 132. Hope Pharmaceuticals Inc Dermatomyositis Drug Product Offered

Table 133. Hope Pharmaceuticals Inc Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 134. Hope Pharmaceuticals Inc Main Business

Table 135. Hope Pharmaceuticals Inc Latest Developments

Table 136. Idera Pharmaceuticals Inc Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. Idera Pharmaceuticals Inc Dermatomyositis Drug Product Offered

Table 138. Idera Pharmaceuticals Inc Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 139. Idera Pharmaceuticals Inc Main Business

Table 140. Idera Pharmaceuticals Inc Latest Developments

Table 141. KPI Therapeutics Inc Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. KPI Therapeutics Inc Dermatomyositis Drug Product Offered

Table 143. KPI Therapeutics Inc Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 144. KPI Therapeutics Inc Main Business

Table 145. KPI Therapeutics Inc Latest Developments

Table 146. Marathon Pharmaceuticals LLC Basic Information, Dermatomyositis Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. Marathon Pharmaceuticals LLC Dermatomyositis Drug Product Offered

Table 148. Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 149. Marathon Pharmaceuticals LLC Main Business

Table 150. Marathon Pharmaceuticals LLC Latest Developments

List of Figures

Figure 1. Picture of Dermatomyositis Drug

Figure 2. Dermatomyositis Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Dermatomyositis Drug Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Dermatomyositis Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Dermatomyositis Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Abatacept

Figure 10. Product Picture of Baricitinib

Figure 11. Product Picture of Dalazatide

Figure 12. Product Picture of Immune Globulin

Figure 13. Product Picture of IMO-8400

Figure 14. Product Picture of Others

Figure 15. Global Dermatomyositis Drug Sales Market Share by Type in 2021

Figure 16. Global Dermatomyositis Drug Revenue Market Share by Type (2017-2022)

Figure 17. Dermatomyositis Drug Consumed in Hospital

Figure 18. Global Dermatomyositis Drug Market: Hospital (2017-2022) & (K Pcs)

Figure 19. Dermatomyositis Drug Consumed in Clinic

Figure 20. Global Dermatomyositis Drug Market: Clinic (2017-2022) & (K Pcs)

Figure 21. Dermatomyositis Drug Consumed in Others

Figure 22. Global Dermatomyositis Drug Market: Others (2017-2022) & (K Pcs)

Figure 23. Global Dermatomyositis Drug Sales Market Share by Application (2017-2022)

Figure 24. Global Dermatomyositis Drug Revenue Market Share by Application in 2021

Figure 25. Dermatomyositis Drug Revenue Market by Company in 2021 ($ Million)

Figure 26. Global Dermatomyositis Drug Revenue Market Share by Company in 2021

Figure 27. Global Dermatomyositis Drug Sales Market Share by Geographic Region (2017-2022)

Figure 28. Global Dermatomyositis Drug Revenue Market Share by Geographic Region in 2021

Figure 29. Global Dermatomyositis Drug Sales Market Share by Region (2017-2022)

Figure 30. Global Dermatomyositis Drug Revenue Market Share by Country/Region in 2021

Figure 31. Americas Dermatomyositis Drug Sales 2017-2022 (K Pcs)

Figure 32. Americas Dermatomyositis Drug Revenue 2017-2022 ($ Millions)

Figure 33. APAC Dermatomyositis Drug Sales 2017-2022 (K Pcs)

Figure 34. APAC Dermatomyositis Drug Revenue 2017-2022 ($ Millions)

Figure 35. Europe Dermatomyositis Drug Sales 2017-2022 (K Pcs)

Figure 36. Europe Dermatomyositis Drug Revenue 2017-2022 ($ Millions)

Figure 37. Middle East & Africa Dermatomyositis Drug Sales 2017-2022 (K Pcs)

Figure 38. Middle East & Africa Dermatomyositis Drug Revenue 2017-2022 ($ Millions)

Figure 39. Americas Dermatomyositis Drug Sales Market Share by Country in 2021

Figure 40. Americas Dermatomyositis Drug Revenue Market Share by Country in 2021

Figure 41. United States Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 42. Canada Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. Mexico Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 44. Brazil Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 45. APAC Dermatomyositis Drug Sales Market Share by Region in 2021

Figure 46. APAC Dermatomyositis Drug Revenue Market Share by Regions in 2021

Figure 47. China Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Japan Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. South Korea Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Southeast Asia Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. India Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 52. Australia Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 53. Europe Dermatomyositis Drug Sales Market Share by Country in 2021

Figure 54. Europe Dermatomyositis Drug Revenue Market Share by Country in 2021

Figure 55. Germany Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. France Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. UK Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Italy Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 59. Russia Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 60. Middle East & Africa Dermatomyositis Drug Sales Market Share by Country in 2021

Figure 61. Middle East & Africa Dermatomyositis Drug Revenue Market Share by Country in 2021

Figure 62. Egypt Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. South Africa Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. Israel Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Turkey Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 66. GCC Country Dermatomyositis Drug Revenue Growth 2017-2022 ($ Millions)

Figure 67. Manufacturing Cost Structure Analysis of Dermatomyositis Drug in 2021

Figure 68. Manufacturing Process Analysis of Dermatomyositis Drug

Figure 69. Industry Chain Structure of Dermatomyositis Drug

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles